	Name of the Issuer:	Yash Optics & Lens Limited	Last updated on	08-Apr-24	
1	Type of Issue (IPO / FPO)	IPO			
2	Offer Size (Rs. Cr)*				
	- Fresh Issue Size (Rs. Cr)	53.15			
	*Source: Prospectus dated April 04, 2024 and Final Post issue report of	lated April 08, 2024.			
3	Grade of issue along with name of the rating agency				
	Name	Not Applicable			
	Grade	Not Applicable			
4	Subscription Level (Number of times)	39.09*			
	Source: Final Post issue report dated April 08, 2024				
	*The above figure is after technical rejections				

## 5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) allotment in the issue (1)	11.58%
(ii) at the end of 1st Quarter immediately after the listing	0.00%
(iii) at the end of 1st FY (March 31, 2025)*	Not Available
(iv) at the end of 2nd FY (March 31, 2026)*	Not Available
(v) at the end of 3rd FY (March 31, 2027)*	Not Available

<sup>\*</sup>QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.

# 6 Financials of the issuer (Consolidated)

· mandalo or the locati (consolitation)			(In Rs. Lacs)	
Parameters	1st FY	2nd FY	3rd FY	
raidifieters	(March 31, 2025)*	(March 31, 2026)*	(March 31, 2027)*	
Income from operations	Not Available	Not Available	Not Available	
Net Profit for the period	Not Available	Not Available	Not Available	
Paid-up equity share capital	Not Available	Not Available	Not Available	
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available	

<sup>\*</sup>Financials not disclosed as the same is in process of being prepared.

7 Trading Status in the scrip of the issuer Company's Equity Shares are listed on SME Platform of NSE Limited (NSE Emerge) The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)*	Not Available
(ii) at the end of 2nd FY (March 31, 2026)*	Not Available
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available

<sup>\*</sup>Trading status not disclosed as the relevant fiscal year has not been completed.

# 8 Change in Directors of issuer from the disclosures in the offer document

Name of the Director	Appointed / Resigned
-	-
-	-
-	-
	Name of the Director

Source: Stock Exchange Filings

<sup>(1)</sup> Source: Basis of Allotment

<sup>\*</sup> Changes in Directors of Issuer not updated as the relevant financial years have not been completed

# 9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document

Not applicable

(ii) Actual implementation

Not applicable

(iii) Reasons for delay in implementation, if any

Not applicable

# 10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

	(Rs. Crore)
Objects of the Fresh Issue	Amount
Funding of Capital expenditure for setting up a manufacturing unit	18.25
for backward integration	
Purchase of Plant and Machinery at existing manufacturing unit	11.86
Repayment/ prepayment of certain borrowings availed by our	6.00
Company	
Funding Working Capital Requirements of our Company and	10.00
General Corporate Purpose	3.78
Total	49.89
Source: Proposition dated April 02, 2024	•

Source: Prospectus dated April 03, 2024

### (ii) Actual utilization

	(Rs. Crore)	
Objects of the Fresh Issue	Amount	
Repayment or prepayment, in full or in part, of borrowings availed	Not Available	
Acquisition of land	Not Available	
Funding of capital expenditure requirements of our Company	Not Available	
towards set up of Solar Power Plant	Not Available	
General Corporate Purpose	Not Available	
Total	Not Available	

(iii) Reasons for deviation, if any Not applicable

# Comments of monitoring agency

(a) Comments on use of funds

(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document

Not Applicable, since Issue size is less than Rs. 100 crores

(c) Any other reservations expressed by the monitoring agency about the end use of funds

12 Pricing Data

Issue Price (Rs.):

81 NSE 08-Apr-24

Designated Stock Exchange: Listing Date:

Price parameters	At close of At clo listing day (April 08, 2024)	t close of 30th calendar day from listing day (May 07, 2024) <sup>(1)</sup>	At close of 90th calendar day from listing day (July 06, 2024) <sup>(2)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2025)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	92.7	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50	22,666.30	Not Available	Not Available	Not Available	Not Available	Not Available

Price parameters	As at the en	d of 2nd FY after the listing of the is (March 31, 2026) <sup>(3)(4)</sup>	ssue	As at the end of 3rd FY aft (March 31,	•	sue
Trice parameters	Closing price	High	Low	Closing price	High	Low
	Closing price	(during the FY)	(during the FY)	Closing price	(during the FY) (d	(during the FY)
Market Price on NSE	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIETY 50	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

<sup>\*</sup>Being index of NSE, the designated stock exchange

- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
- (2) 90th calendar day shall be taken as listing date plus 89 calendar days.
- (3) High and Low based on intra day prices
- (4) Pricing data not disclosed as the relevant fiscal year has not completed
- (5) In case of any reporting day falling on a holiday, previous trading day prices has been disclosed.

#### 13 Basis for Issue Price

Accounting ratio		As disclosed in the offer	At the end of 1st FY (March 31,	At the end of 2nd FY (March 31,	At the end of 3rd FY
Accounting ratio		document <sup>(1)</sup>	2025)	2026) <sup>(2)</sup>	(March 31, 2027) <sup>(2)</sup>
	Issuer:	4.55	Not Available	Not Available	Not Available
EPS	Peer Group:				
	GKB Ophthalmics Ltd	(5.72)	Not Available	Not Available	Not Available
	Issuer:	17.8	Not Available	Not Available	Not Available
Price to Earnings Ratio (P/E)	Peer Group:				
	GKB Ophthalmics Ltd	(16.58)	Not Available	Not Available	Not Available
	Issuer:	10.79	Not Available	Not Available	Not Available
NAV	Peer Group:				
	GKB Ophthalmics Ltd	5.46	Not Available	Not Available	Not Available
	Issuer:	42.20%	Not Available	Not Available	Not Available
RoNW(%)	Peer Group:				
	GKB Ophthalmics Ltd	10.47%	Not Available	Not Available	Not Available

### Notes:

- (1) Sourced from Prospectus dated April 04, 2024
- (2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

- (i) Earnings per Equity Share are computed in accordance with Accounting Standard 20 "earnings per Share" notified by the Companies (Accounting Standards) Rules, 2006.
- (ii) NAV per share Net asset value per Equity Share represents net worth as at the end of the Fiscal divided by the number of Equity Shares outstanding at the end of the Fiscal
- (iii) P/E Closing Market Price as of relevant fiscal year end / Basic EPS for the Fiscal
- (iv) RoNW Return on net worth (%) is net profit attributable to equity shareholders divided by net worth for the Fiscal

### 14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
Not Applicable	Not Applicable

### Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by Shreni Shares Limited ("Shreni") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the NSE Limited ("NSE") and the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges"), as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.